{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T03:43:01Z","timestamp":1767066181154,"version":"build-2065373602"},"reference-count":58,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.canrad.2019.03.009","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T08:12:37Z","timestamp":1563523957000},"page":"432-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?"],"prefix":"10.1016","volume":"23","author":[{"given":"A.","family":"Wrona","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2019.03.009_bib0295","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0300","doi-asserted-by":"crossref","first-page":"iii4","DOI":"10.1093\/annonc\/mdw301","article-title":"The role of the ALK receptor in cancer biology","volume":"27","author":"Hallberg","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0305","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3111\/13696998.2014.1003644","article-title":"Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden","volume":"18","author":"Guerin","year":"2015","journal-title":"J Med Econ"},{"key":"10.1016\/j.canrad.2019.03.009_bib0310","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canrad.2019.03.009_bib0315","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.lungcan.2013.01.019","article-title":"ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer","volume":"80","author":"Preusser","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canrad.2019.03.009_bib0320","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1200\/JCO.2012.48.2141","article-title":"Cystic brain metastasis in non-small-cell lung cancer with ALK rearrangement","volume":"32","author":"Hayashi","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0325","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/JTO.0000000000000409","article-title":"Cystic brain metastases in NSCLC harboring the EML4-ALK translocation after treatment with crizotinib","volume":"10","author":"Saraceni","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0330","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1097\/JTO.0000000000000029","article-title":"The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer","volume":"8","author":"Gainor","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0335","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.lungcan.2012.08.015","article-title":"Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report","volume":"78","author":"Falk","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canrad.2019.03.009_bib0340","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/neuonc\/nou146","article-title":"Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases","volume":"17","author":"Mak","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0345","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/neuonc\/nov043","article-title":"Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?","volume":"17","author":"Wang","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0350","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/JCO.2015.62.0138","article-title":"Extended survival and prognostic factors for patients with ALK-Rearranged non-small-cell lung cancer and brain metastasis","volume":"34","author":"Johung","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0355","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2019.03.009_bib0360","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.4161\/cbt.22255","article-title":"Isolated central nervous system progression on crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?","volume":"13","author":"Chun","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.canrad.2019.03.009_bib0365","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","article-title":"Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases","volume":"33","author":"Costa","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0370","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1200\/JCO.2015.63.5888","article-title":"Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014","volume":"34","author":"Solomon","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0375","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1097\/JTO.0000000000000038","article-title":"Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer","volume":"8","author":"Peled","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0380","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1097\/JTO.0b013e3182762d20","article-title":"High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer","volume":"8","author":"Gandhi","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0385","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1535-7163.MCT-12-0868","article-title":"ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK","volume":"12","author":"Sun","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.canrad.2019.03.009_bib0390","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.radonc.2014.12.009","article-title":"Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer","volume":"114","author":"Dai","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0395","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lungcan.2016.03.008","article-title":"Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation","volume":"96","author":"Ou","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canrad.2019.03.009_bib0400","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01616412.1999.11740920","article-title":"Early decrease of P-glycoprotein in the endothelium of the rat brain capillaries after moderate dose of irradiation","volume":"21","author":"Mima","year":"1999","journal-title":"Neurol Res"},{"key":"10.1016\/j.canrad.2019.03.009_bib0405","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/JTO.0000000000000468","article-title":"CSF concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment","volume":"10","author":"Metro","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0410","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijrobp.2005.01.039","article-title":"Molecular targets in radiation-induced blood-brain barrier disruption","volume":"62","author":"Nordal","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.03.009_bib0415","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1158\/0008-5472.CAN-06-2802","article-title":"Sphingosine-1-phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damage-induced mitotic death","volume":"67","author":"Bonnaud","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.canrad.2019.03.009_bib0420","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.2011.41.0639","volume":"31","author":"Soffietti","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0425","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0430","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/1097-0142(195407)7:4<682::AID-CNCR2820070409>3.0.CO;2-S","article-title":"Roentgen-ray therapy of cerebral metastases","volume":"7","author":"Chao","year":"1954","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2019.03.009_bib0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0360-3016(80)90195-9","article-title":"The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group","volume":"6","author":"Borgelt","year":"1980","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.03.009_bib0440","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","volume":"388","author":"Mulvenna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2019.03.009_bib0445","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/neuonc\/nov186","article-title":"Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study","volume":"18","author":"Habets","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0450","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0455","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"Jama"},{"key":"10.1016\/j.canrad.2019.03.009_bib0460","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/cncr.26515","article-title":"A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases","volume":"118","author":"Tsao","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2019.03.009_bib0465","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijrobp.2017.04.037","article-title":"A multi-institutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901 Study Update): irradiation-related complications and long-term maintenance of mini-mental state examination scores","volume":"99","author":"Yamamoto","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.03.009_bib0470","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3857\/roj.2015.33.3.207","article-title":"Stereotactic radiosurgery for brain metastasis in non-small cell lung cancer","volume":"33","author":"Won","year":"2015","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.canrad.2019.03.009_bib0475","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3340\/jkns.2015.58.3.217","article-title":"Efficacy and Safety of fractionated stereotactic radiosurgery for large brain metastases","volume":"58","author":"Jeong","year":"2015","journal-title":"J Korean Neurosurg Soc"},{"key":"10.1016\/j.canrad.2019.03.009_bib0480","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/neuonc\/not114","article-title":"Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Brown","year":"2013","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0485","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.ijrobp.2010.01.039","article-title":"Hippocampal-sparing whole-brain radiotherapy: a \u201chow-to\u201d technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy","volume":"78","author":"Gondi","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2019.03.009_bib0490","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","article-title":"Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer","volume":"7","author":"Weickhardt","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0495","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.radonc.2017.03.007","article-title":"Treatment options for patients with brain metastases from EGFR\/ALK-driven lung cancer","volume":"123","author":"Doherty","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0500","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00280-014-2578-6","article-title":"Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases","volume":"74","author":"Kodama","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0505","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0510","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0515","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.2015.63.9443","article-title":"Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase ii global study","volume":"34","author":"Ou","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0520","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2019.03.009_bib0525","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","article-title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0530","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/S1556-0864(16)30251-9","article-title":"141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated. ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials","volume":"11","author":"Felip","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0535","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/S1556-0864(16)30245-3","article-title":"1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1\/2 trial","volume":"11","author":"Rosell","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0540","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0545","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1200\/JCO.2017.77.5841","article-title":"Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials","volume":"36","author":"Camidge","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0550","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2019.03.009_bib0555","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0560","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0565","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/JCO.2015.63.9682","article-title":"CNS metastases in patients with non-small-cell lung cancer and ALK Gene rearrangement","author":"Shi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0570","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1200\/JCO.2016.67.2410","article-title":"Management of brain metastases in ALK-positive non-small-cell lung cancer","volume":"34","author":"Rusthoven","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2019.03.009_bib0575","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ctrv.2018.10.011","article-title":"Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors","volume":"71","author":"Wrona","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.canrad.2019.03.009_bib0580","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2017.08.014","article-title":"Hypofractionated stereotactic radiation therapy to the resection bed for intracranial metastases","volume":"99","author":"Keller","year":"2017","journal-title":"Int J Radiat Onco Biol Phys"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321819301453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321819301453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:31:05Z","timestamp":1761136265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321819301453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1278321819301453"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2019.03.009","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2019.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}